Best Practice Update on Clostridium difficile Infection: Focus on Prevention, Treatment and Recurrence
Clostridium difficile infection (CDI) is the most common healthcare associated infection the United States and the most common cause of mortality in patients with gastroenteritis. Treatment of CDI is evolving with a greater emphasis on prevention of recurrence also known as sustained clinical response. These changes will require education to clinicians on these major changes. This activity provides a state-of-the art update on best practice treatment of CDI with a focus on guideline updates, antibiotic stewardship strategies, and sustained clinical response.
As the first of two modules in this series, this activity prepares the learner for Module 2, which explores these challenges using patient cases.
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to- Review updates of Clostridium difficile infection (CDI) guideline recommendations
- Apply antibiotic stewardship strategies for the primary prevention of CDI
- Discuss treatment of CDI with a focus on sustained clinical response
Faculty
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with Clostridium difficile infection (CDI).
This online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals listed have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
- Kevin Garey
- Merck, Inc., Summit Therapeutics, and Tetraphase: Research Support
- Krishna Rao
- Merck, Inc.: Research support (Co-investigator)
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to link to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-18425-H01-P
Release Date: Friday, November 16, 2018
Expiration Date: Sunday, March 1, 2020
Activity Type: Application-based
CE Credits: 1.0
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.